Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04702880 · ClinicalTrials.gov registry record · Phase 2

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

A Phase 2 study of Extensive-stage Small-cell Lung Cancer, sponsored by Bristol-Myers Squibb.

Active
Registry status
Phase 2
Development phase
120
Enrollment target
20
Study locations

NCT04702880 is a Phase 2 study of Extensive-stage Small-cell Lung Cancer that is active but no longer recruiting, run by Bristol-Myers Squibb. The registered enrollment target is 120 participants, below the 171-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04702880, a Phase 2 study of Extensive-stage Small-cell Lung Cancer, is active but no longer recruiting, sponsored by Bristol-Myers Squibb.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
120 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer (ES-SCLC).

Conditions Studied

Extensive-stage Small-cell Lung Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Etoposide
  • BIOLOGICAL Nivolumab
  • BIOLOGICAL BMS-986012

Study Locations (20)

Other

  • Local Institution - 0034 - Ghent
  • Local Institution - 0050 - Liège
  • Local Institution - 0036 - Athens
  • Local Institution - 0038 - Athens

Ohio

  • Local Institution - 0060 - Cincinnati
  • Local Institution - Cincinnati
  • Local Institution - 0067 - Cleveland

Alabama

  • Local Institution - 0075 - Birmingham

New Jersey

  • Local Institution - 0022 - Hackensack

North Carolina

  • Local Institution - 0002 - Durham

Tennessee

  • Local Institution - 0081 - Nashville

Texas

  • Local Institution - Dallas

New South Wales

  • Local Institution - 0003 - Westmead

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2021-03-17
Est. Completion 2025-12-31
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04702880

The ClinicalTrials.gov registry entry for NCT04702880 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 171-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (30% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.

NCT04702880 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Ohio, Alabama.

Frequently Asked Questions

What is clinical trial NCT04702880 about?

NCT04702880 is a clinical study titled "A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer". The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed pa...

What is the current status of trial NCT04702880?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2021-03-17. Estimated completion is 2025-12-31.

What conditions does trial NCT04702880 study?

This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.

What interventions are being tested in trial NCT04702880?

The interventions under investigation include: Carboplatin (DRUG), Etoposide (DRUG), Nivolumab (BIOLOGICAL), BMS-986012 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04702880?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04702880 being conducted?

This trial has 20 study locations across Alabama, New Jersey, North Carolina, Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Extensive-stage Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Extensive-stage Small-cell Lung Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.